Trial Profile
The efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Oct 2014
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Oct 2014 Status changed from not yet recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 31 Jul 2013 New trial record